[Bright Peptides](/) · [Skin tone](/skin-tone) · [Peptide names](/compare) · [Licensed review](/access)

# What a prescription can and can't tell you

A product page can show that a service offers something. It can't decide whether it fits you or prove the result you're hoping for.

![An open lemon awning over a modest apartment balcony with a chair and drying laundry](/bright-day-ccbbb86e84a8/open-awning.webp)

A yellow awning shades a balcony with a chair and drying laundry.

## Start with the cream or injection question

The route matters. A [review of topical GHK](https://pmc.ncbi.nlm.nih.gov/articles/PMC11830136/) discusses getting the ingredient through skin's outer layer. It doesn't show what injecting GHK-Cu does in people. A cream paper can't carry an injection claim.

GHK-Cu has no FDA-approved medicine. The FDA also explains that [a product's intended use affects its category](https://www.fda.gov/cosmetics/cosmetics-laws-regulations/it-cosmetic-drug-or-both-or-it-soap). Calling something skincare doesn't settle the rules when its claims go beyond appearance.

## What licensed review means here

Promise Peptides offers GHK-Cu prescription care through licensed U.S. providers at mypromise.com. A provider assesses the request and can decide against prescribing. Care is limited to U.S. patients, and options depend on the state and treatment. The [home-page prescription link](/#prescription) leads to its GHK-Cu information.

That describes access. It doesn't add to the evidence for a skin result, and it doesn't turn a compounded medicine into an approved drug. The personal decision and the research question still need their own answers.

## A prescription isn't FDA product approval

Compounding means mixing, combining or changing ingredients to make a medicine for a patient's particular needs. It doesn't give that product FDA approval. FDA's [guide to compounding risks](https://www.fda.gov/drugs/human-drug-compounding/understanding-risks-compounded-drugs) explains the missing checks:

Before marketing, the agency hasn't checked how well these medicines work, whether they're safe or the quality of their preparation. A prescription doesn't add that assessment.

There's another phrase worth slowing down for. The [FDA safety record](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks) carries an April 22, 2026 content date. It lists injectable GHK-Cu and Melanotan II under “nominated but withdrawn,” alongside the safety concerns. The nominators took back their requests.

Neither entry supplies a withdrawal date. Withdrawal brings no FDA clearance and no permission to compound. GHK-Cu's non-injectable forms have a separate record, so the injected form's entry can't describe every use of the peptide.

## A few questions for the conversation

### What was actually tested?

The preparation, route and skin goal need to match the evidence. A finding in cells isn't a result in people. A study of one mixture doesn't establish what a different preparation does.

### What remains uncertain?

The discussion can cover possible harms, what a benefit would look like and how a problem would be handled. A clinician can consider your health history; a general guide can't complete that review.

### Does location matter?

Yes. [HHS explains that licensing across state lines varies](https://telehealth.hhs.gov/licensure/licensing-across-state-lines). An online visit doesn't create nationwide permission to prescribe. Bright Peptides gives no medical advice, sets no dose and arranges no appointments.

Bright Peptides offers a window into skin research, as a guide rather than a clinic, pharmacy or seller.

© 2026 Bright Peptides.

[GHK-Cu](/ghk-cu) · [Melanotan II](/melanotan-2) · [Reading list](/references) · [About](/about) · [Contact](/contact)